B. Riley Comments on RadNet’s Q3 Earnings (NASDAQ:RDNT)

RadNet, Inc. (NASDAQ:RDNT) – B. Riley raised their Q3 2025 earnings per share estimates for RadNet in a report issued on Tuesday, August 12th. B. Riley analyst Y. Zhi now anticipates that the medical research company will earn $0.19 per share for the quarter, up from their previous forecast of $0.18. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for RadNet’s current full-year earnings is $0.56 per share. B. Riley also issued estimates for RadNet’s Q4 2025 earnings at $0.23 EPS.

Several other equities research analysts also recently issued reports on the company. Wall Street Zen downgraded RadNet from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th. Truist Financial set a $74.00 target price on RadNet in a research report on Thursday, July 10th. Raymond James Financial restated a “strong-buy” rating and set a $75.00 target price (up previously from $66.00) on shares of RadNet in a research report on Wednesday. Finally, Morgan Stanley upgraded RadNet to an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, RadNet currently has an average rating of “Buy” and an average target price of $71.60.

RadNet Trading Up 0.5%

NASDAQ:RDNT opened at $68.75 on Wednesday. The company has a market cap of $5.29 billion, a P/E ratio of -343.73 and a beta of 1.43. The stock’s fifty day moving average price is $57.20 and its two-hundred day moving average price is $55.95. RadNet has a 1 year low of $45.00 and a 1 year high of $93.65. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.00 and a quick ratio of 2.01.

RadNet (NASDAQ:RDNT) last posted its earnings results on Sunday, August 10th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.14. The firm had revenue of $498.23 million for the quarter, compared to the consensus estimate of $488.06 million. RadNet had a positive return on equity of 2.41% and a negative net margin of 0.78%. The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.16 earnings per share.

Institutional Investors Weigh In On RadNet

Institutional investors and hedge funds have recently made changes to their positions in the business. American Century Companies Inc. raised its position in RadNet by 507.9% during the first quarter. American Century Companies Inc. now owns 1,272,928 shares of the medical research company’s stock valued at $63,290,000 after purchasing an additional 1,063,516 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in RadNet by 81.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,657,613 shares of the medical research company’s stock valued at $82,417,000 after purchasing an additional 743,922 shares in the last quarter. Alyeska Investment Group L.P. raised its position in RadNet by 141.7% during the first quarter. Alyeska Investment Group L.P. now owns 1,214,882 shares of the medical research company’s stock valued at $60,404,000 after purchasing an additional 712,270 shares in the last quarter. Nuveen LLC purchased a new stake in RadNet during the first quarter valued at about $27,422,000. Finally, Norges Bank purchased a new stake in RadNet during the second quarter valued at about $31,051,000. Hedge funds and other institutional investors own 77.90% of the company’s stock.

Insider Activity

In related news, EVP Alma Gregory Sorensen sold 55,000 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $56.48, for a total value of $3,106,400.00. Following the sale, the executive vice president owned 1,160,509 shares in the company, valued at approximately $65,545,548.32. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 5.60% of the company’s stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.